The Service Line

The company that owns the largest drug-benefit manager and the largest drugstore chain says it will stop owning both together, and the pharmacy side is the one that leaves. CVS Health said on November 4 that it intends to separate into two independent, publicly traded companies, according to its CVS Health announcement. The healthcare solutions company keeps Aetna, CVS Caremark (the pharmacy benefit manager, or PBM), CVS Specialty, Oak Street Health and Signify Health. A new company called CVS Pharmacy gets about 9,000 stores, mail pharmacy, MinuteClinic and the Health100 technology unit, with Prem Shah as chief executive. The release targets the first half of 2028, calls the split intended to be tax-free, and lists conditions including final board approval and an effective Form 10 registration statement with the Securities and Exchange Commission. It gives no deal value and says nothing about the commercial contract between the two companies or about the state laws that ban PBM-owned pharmacies. For an independent pharmacy owner, the open question is whether Caremark will treat CVS Pharmacy as just another network pharmacy; the release says only that CVS Pharmacy will pursue partnerships with payers, PBMs and manufacturers. Confidence: High on the structure and timing (company release); Low on what it does to network terms, since nothing is disclosed.

Reimbursement: The Labor Department made PBM fee disclosure final, with audit rights that run 60 days

The Labor Department issued its final rule requiring PBMs to disclose their compensation to large self-insured employer health plans on October 29, and it was published in the Federal Register on November 2. This updates our coverage of the rule clearing White House review. The Federal Register notice (document 2026-22306) is the primary text; we could not extract its text this run, so the details below come from Mayer Brown and Troutman Pepper Locke. They report an effective date of January 4, 2027, application to plan years beginning on or after July 1, 2027, and coverage of self-insured plans with at least 100 employees. PBMs would disclose rebates and fees by drug, spread by National Drug Code (NDC) and channel, and net price per drug, with semiannual reports that include claim-level spread. Plans get an annual audit right: the PBM must confirm within 10 business days and produce claims data and its pharmacy and manufacturer contracts within 60 days. The summaries do not give a savings estimate, so treat any figure you see as unconfirmed until you read the preamble. For pharmacies, the claim-level spread data is what makes employer audits of what the PBM paid you versus what it charged the plan possible. Confidence: Medium, law firm summaries of a rule whose text we could not read.

Enforcement: A House committee asked the three largest PBMs whether audits of independent pharmacies were retaliation

House Oversight Committee Chairman James Comer asked CVS Caremark, Express Scripts and Optum Rx on October 23 for records on whether audits of independent pharmacies were timed to punish pharmacies that backed a PBM reform bill. The Committee release says multiple independent pharmacies that supported H.R. 6610, the Pharmacists Fight Back in FEHB Plans Act, received an unusual number of burdensome audit notices after the Committee passed the bill in July. It seeks documents on audit practices, pharmacy selection and nationwide audit totals, plus records on audits of independents in Kentucky, Mississippi and Florida, and cites one audit over a /bin/bash.99 medication that took hundreds of staff hours. These are concerns raised by the Committee, not findings; the release states no deadline and no PBM response, and we could not read the letters. If you are audited, keep a dated log of every notice, the amount at issue and staff hours spent, because that record is what a committee, an attorney general or a court will ask for. Confidence: High that the letters were sent (Committee); Low on whether any audit was retaliatory.

Who’s Buying

The CVS separation above is the week’s ownership story. The scan found no new pharmacy acquisition that was confirmed in a primary source this week.

Clinical Policy

No new utilization or staffing policy shift surfaced in primary sources this week. A frontier scan on pharmacy workforce and cold-chain distribution returned only older material, nothing worth filing.

The Operator Metric: 5%

Under the Labor Department rule as summarized by law firms, a PBM must explain any compensation category that comes in 5% or more above its earlier estimate, unless the parties agree to a lower threshold. Mayer Brown’s summary also reports that PBMs must give advance notice of formulary changes expected to raise manufacturer payments by 5% or more, though no fixed notice period was set. If you contract with employers or advise self-insured plans, ask whether their PBM agreement sets a tighter variance trigger than 5%, and which line items it covers. For a pharmacy owner, compare each plan’s quarterly reimbursement against the NDC-level spread data once it flows. Confidence: Medium, law firm summaries, not the rule text.